Restoring miR-101b levels or inhibiting AMPK can reverse tau pathology and dendritic abnormalities caused by HDAC2 overexpression, both in vitro and in an Alzheimer’s disease mouse model [54]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.